How JD Health’s AI Doctor “Dawei” Boosted User Growth 4× and Redefined Its Value

A mother with a feverish child used JD Health’s AI doctor “Dawei” to obtain a diagnosis and medication without leaving home, illustrating the service’s ability to provide a fast, free, and fully online medical entry point.

JD Health’s 2026 mid‑year report showed total revenue of RMB 409 billion (up 15.9% YoY) and non‑IFRS operating profit of RMB 35 billion (up 40.3% YoY). The report highlighted AI as a key growth driver, noting that “Dawei” now covers over 1,000 disease categories, with user numbers increasing nearly four‑fold during the 618 shopping period and satisfaction exceeding 98%.

In a typical consultation, “Dawei” begins by asking follow‑up questions about symptom duration, accompanying signs such as cough or vomiting, and uses visual selection tools for symptoms that are hard to describe. After three to four dialogue rounds, it structures the information, infers the most likely condition (e.g., acute upper‑respiratory infection), and cites 14 relevant medical references.

When providing treatment advice, “Dawei” distinguishes between etiological and symptomatic therapy, matches acetaminophen suspension to a specific product, initiates the prescription workflow, and leverages JD’s logistics network to deliver medication within 24 minutes based on the user’s address, inventory, price, and delivery speed.

The article notes that many medical Q&A products see about 70% of users drop after the first query. “Dawei” aims to create a strong sense of resolution so users return for future health issues.

Reliability limits are demonstrated through two cases: a user with leg swelling receives a nuanced recommendation to consider spinal compression or deep‑vein thrombosis and is advised to seek in‑person care for serious signs; another user with a toe callus receives home‑care instructions and only escalates to a dermatologist if symptoms worsen.

Key technical challenges include understanding colloquial user language, sequential decision‑making, and knowing when to stop questioning. JD Health’s data—millions of high‑quality doctor‑patient dialogues—feeds the model, while a team of full‑time doctors and experts translates clinical reasoning into training data.

To ensure safety, JD Health has built over 300 standard clinical pathways covering more than 90% of high‑frequency diseases and established 109 quality‑inspection standards. Models are evaluated offline on typical cases before launch, and a dedicated quality‑inspection model continuously monitors live consultations, routing uncertain cases to human doctors.

Beyond clinical reasoning, “Dawei” must align recommendations with real‑world fulfillment constraints: checking drug availability, regulatory compliance, and delivery feasibility. When multiple suitable drugs exist, the system selects those that can be delivered quickly, balancing safety, timeliness, and cost.

The “Always on” vision extends the service from a single consultation to long‑term health management. With user consent, “Dawei” maintains a long‑term memory of past queries, medication history, and health indicators, enabling proactive reminders (e.g., flu‑season vaccine alerts for COPD patients) and continuous monitoring of chronic conditions.

From an industry perspective, the Chinese “Healthy China” strategy and recent AI‑plus health policies provide regulatory support for such end‑to‑end digital health solutions, positioning JD Health’s AI platform as a data‑driven, full‑chain service asset rather than merely an e‑pharmacy shelf.

Overall, the integration of AI reasoning, extensive medical data, robust clinical pathways, and JD’s logistics network creates a sustainable competitive advantage that justifies a re‑valuation of JD Health’s business beyond traditional drug sales.